Biological ActivityNon-selective somatostatin (sst) receptor antagonist. Blocks the effects of sst on airway β-adrenergic function, CRF-induced suppression of gastric empyting, modulation of ACh release and growth hormone, insulin and glucagon release. Reported to act as an sst receptor agonist in human neuroblastoma cell line SH-SY5Y.
(Modifications: Phe-1 = Aminoheptanoyl-Phe, Trp-1 = DTrp, Thr-4 = Bn-Thr)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Somatostatin antagonist analog increases GH, Ins, and glucagon release in the rat.
Fries et al.
The putative somatostatin antagonist, cyclo-(7-aminoheptanoyl-Phe-D-Trp-Lys-Thr[BZL]), may act as a potent antiproliferative agonist.
Stirnweis et al.
Somatostatin inhibits activation of dorsal cutaneous primary afferents induced by antidromic stimulation of primary afferents from an adjacent segment in the rat.
Guo et al.
Brain Res., 2008;1229:61
Citation for Cyclosomatostatin
The citations listed below are publications that use Tocris products. Selected citations for Cyclosomatostatin include:
1 Citation: Showing 1 - 1
Somatostatin and Ins mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP.
Authors: Elliott Et al.
Am J Physiol Endocrinol Metab 2015;308:E130
No product specific FAQs exist for this product, however you mayView all Peptide FAQs
VersaClone cDNA Plasmids
Reviews for Cyclosomatostatin
There are currently no reviews for this product. Be the first to review Cyclosomatostatin and earn rewards!
Have you used Cyclosomatostatin?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image